Clinical Trials · NCT00006368

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novartis Pharmaceuticals
Enrollment
60
Start date
Jan 1998
Locations
1 site, United States
Primary endpoint
Study in Brain and Central Nervous System Tumors
View Octreotide compound reference